Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 randomized, placebo-controlled trial of APG808 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Next Previous
Trial Profile

A Phase 2 randomized, placebo-controlled trial of APG808 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 808 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions

Most Recent Events

  • 25 Mar 2024 According to an Apogee Therapeutics media release, company plans to initiate this trial in 2025.
  • 06 Mar 2024 According to an Apogee Therapeutics media release, company anticipates Initial proof-of-concept data in asthma expected 1H 2025
  • 06 Mar 2024 According to an Apogee Therapeutics media release, company anticipates Interim data for Phase 1 PK and safety in healthy volunteers expected in 2H 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top